BCRX earnings: next report 2026-08-03, real EPS beat/miss history, analyst consensus Buy, P/E -5.50. Updated 2026-07-23.
BioCryst Pharmaceuticals (BCRX) Research Hub
BioCryst Pharmaceuticals (BCRX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 8.12 USD (-7.83%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -5.50, market cap 1.99B. This hub links to the full technical, earnings and options research available for BCRX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 8.12 USD (-7.83%) |
| 52-week range | 8.105 USD – 11.22 USD |
| Trend regime | Range |
| 14-day RSI | 36.9 (Bearish) |
| Trailing P/E | -5.50 |
| Market cap | 1.99B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-03 |
Available research for BCRX
Covered Call on BCRX: how it works, illustrative setup around the real 8.12 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on BCRX: how it works, illustrative setup around the real 8.12 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on BCRX: how it works, illustrative setup around the real 8.12 USD price, max profit/loss, breakeven and when to use it. Educational.
BCRX technical analysis: range, last 8.12 USD, RSI 36.9, 52w range 8.105 USD–11.22 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is BCRX in?
BioCryst Pharmaceuticals (BCRX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is BCRX in an uptrend or downtrend?
As of 2026-09-11, BCRX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is BCRX's trailing P/E ratio?
BCRX's trailing P/E is -5.50, with a market cap of 1.99B. See the earnings research page for full valuation detail.
When does BCRX next report earnings?
BCRX is next scheduled to report earnings on 2026-08-03, with a consensus EPS estimate of 0.14 USD.